BioCis Pharma Starts Phase IIa Trial in Psoriasis

September 22nd, 2009 HIGH WYCOMBE, England - - For Medical Media Only - Not for Republic of Ireland Media STELARA (ustekinumab) has today been approved by the National Institute for Health and Clinical Excellence (NICE) as a treatment option for adults with moderate to severe plaque psoriasis,(1) a notoriously difficult-to-treat skin condition for which many patients report feeling dissatisfied and frustrated with existing treatment options.(2) STELARA, the first in a new class of biologics for the treatment of psoriasis, works by targeting interleukin-12 (IL-12) and IL-23. It provides visible and significant improvements in psoriasis severity,(3,4) and has the added advantage of a convenient dosing regimen for patients - just five injections per year in comparison to a possible 104 injections with etanercept, a widely prescribed biologic therapy.(5,6) Psoriasis, a chronic, non-contagious autoimmune disease resulting in the overproduction of skin cells, affects around 1.5 million people in the UK; up to 20-30% of whom suffer from the severe form of the disease.(7-9) Psoriasis can have both a significant physical and psychological impact on patients.

September 9th, 2009 LEIDEN, The Netherlands - The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute.

September 1st, 2009 BASEL and REINACH, Switzerland - - CAPRA-2-Data Will be Used to File for US Marketing Approval Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM). The CAPRA-2 study (Circadian Administration of Prednisone in Rheumatoid Arthritis-2) was a 12-week, multicentre, double-blind phase III trial evaluating the safety and efficacy of Lodotra(TM) for the treatment of rheumatoid arthritis ("RA"), a chronic, progressive and disabling autoimmune disorder.

June 25th, 2009 OSLO, Norway - Clavis Pharma ASA (OSE: CLAVIS) today announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the "Private Placement"). The Private Placement took place through a bookbuilding process and was managed by Carnegie ASA and DnB NOR Markets as joint-lead managers and joint bookrunners.

June 3rd, 2009 MAIDENHEAD, England - CHMP Recommends Approval of a Continuous Dosing Regimen Option for Enbrel In Plaque Psoriasis, and a New Pre-Filled Pen Delivery Device Today, Wyeth received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for two recent submissions relating to Enbrel(R) (etanercept), the tumour necrosis factor alpha inhibitor treatment for plaque psoriasis, rheumatoid arthritis and other related inflammatory conditions. Enbrel is currently approved for intermittent treatment of adult plaque psoriasis: if approved by the European Commission following the Committee's recommendation, Enbrel will become the first and only biologic treatment indicated for both continuous and intermittent treatment of adult plaque psoriasis.

May 5th, 2009 STOCKHOLM - Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease.

May 5th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, announces today that the Company's Investigational New Drug Application (IND) to conduct a Phase III clinical trial of Catioprost(R) (Nova21027), for the treatment of glaucoma has been granted by the U.S. Food and Drug Administration (FDA).

April 28th, 2009 STOCKHOLM, Sweden - Results to be Presented at World Congress of Nephrology 2009 Pharmalink AB announced today that it has completed its open Phase II trial evaluating the efficacy and safety of Nefecon(R) in IgA nephropathy, a glomerulonephritis leading to end-stage renal disease. Nefecon is an enteric formulation of a locally acting corticosteroid which downregulates the inflammatory process in the kidneys through suppression of the gut immune system.

April 14th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome.

March 25th, 2009 AMSTERDAM - Psoriasis Patients from Around the World Come together to Bare Their Skin and Share Their Stories for New Pan-European Educational Programme AMSTERDAM, March 26 /PRNewswire/ -- Psoriasis: The Naked Truth, a new pan-European educational programme to expose the physical and emotional impact of living with psoriasis, launches today. The centerpiece of the programme is a photo exhibit that captures the experience of living with psoriasis through portrait photography by award winning photographer Ralf Tooten and features the personal stories of men and women living with the disease.

May 7th, 2009 LUCKNOW - Polling began in 18 of Uttar Pradesh's 80 Lok Sabha polls in the fourth phase of general elections Thursday morning. Polling began at 7 aa.m.

July 25th, 2009 NEW DELHI - Ahead of throwing open the track from Yamuna Bank to Noida across the state border from east Delhi, Delhi Metro began trial runs Saturday on a section of the route, a Metro official said. The trial run, which began at 10 a.m., was conducted only till the New Ashok Nagar station in east Delhi.

April 14th, 2009 HYDERABAD - GVK Biosciences (GVK BIO), Asia's leading integrated research services provider and Excel PharmaStudies (Excel), a leading Chinese Clinical Research Organization announced a strategic alliance to conduct clinical trials in Asia. The alliance provides clinical trial sponsors access to the scientific skills, talent pool, flexible resourcing, and cost-effectiveness of both India and China.

May 22nd, 2009 NEW DELHI - Trial runs for the the newly procured broad gauge train that would ply on phase II of the Delhi Metro began here Friday. 'The trial run was carried out between 3 a.m.

March 5th, 2009 NEW DELHI - The second phase of weapon testing on the indigenous light combat aircraft (LCA) Tejas has begun successfully in the northwestern sector with the jet scoring a direct hit on target, an official said Thursday. The focus of the current phase of testing, being held at an airbase in the northwestern sector, is on 'safe separation' - or the weapon leaving the jet safely - and accuracy of weapon delivery.

September 30th, 2009 NEW DELHI - Home Minister P. Chidambaram Wednesday scoffed at Pakistan for terming as "half-baked" India's evidence of Lashkar-e-Taiba founder Hafiz Saeeds role in the 26/11 Mumbai mayhem.

April 18th, 2009 NEW DELHI - The last day for filing of nominations for the fourth phase of the ongoing parliamentary elections concluded on Saturday. Elections for the fourth phase of the Lok Sabha polls are scheduled to be held for 85 seats on May 7, 2009.

April 14th, 2009 NEW DELHI - The Election Commission has reiterated that the result of opinion/exit polls should not be published from Tuesday evening till the conclusion of polls May 13. 'The result of opinion/exit polls carried out at any time cannot be published, publicised or disseminated in any manner, during the period starting from 48 hours before the hour fixed for conclusion of poll in the first phase of election and till the conclusion of poll in the last phase of election,' the Election Commission said in a statement Tuesday.

April 20th, 2009 NEW DELHI - Nearly 300 candidates with criminal records from different political parties are fighting the second phase of Lok Sabha polls on April 23, with the Congress party topping the list with 40, according to a survey. According to an analysis by an NGO, National Election Watch, of the 1,425 candidates in the fray for the second phase, 288 have criminal records.

April 20th, 2009 NEW DELHI - Nearly 300 candidates with criminal records from different political parties are fighting the second phase of Lok Sabha polls on April 23, with the Congress party topping the list with 40, according to a survey. According to an analysis by an NGO, National Election Watch, of the 1,425 candidates in the fray for the second phase, 288 have criminal records.